Placebo intravenous

DRUG6 trials

Sponsors

Eli Lilly and Company, Astellas Pharma Europe B.V., Pharmamel S.L., Boehringer Ingelheim

Conditions

COVID-19Coronavirus InfectionHealthy SubjectsHealthy VolunteersPharmacokinetics of ASP6294PsoriasisSARS-CoV 2

Phase 1

A Study of LY3016859 in Healthy Volunteers

CompletedNCT01545583

Eli Lilly and CompanyHealthy Volunteers

Start: 2012-04-30End: 2012-09-30Updated: 2018-07-19

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

CompletedNCT02681861

Astellas Pharma Europe B.V.Healthy Subjects, Pharmacokinetics of ASP6294

Start: 2016-01-31End: 2016-12-31Updated: 2017-01-10

Phase 2

A Study for Adults With Plaque Psoriasis

TerminatedNCT01018810

Eli Lilly and CompanyPsoriasis

Start: 2009-12-31End: 2010-08-31Updated: 2011-07-29

Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19

CompletedNCT04568863

Pharmamel S.L.Coronavirus Infection, COVID-19, SARS-CoV 2

Start: 2020-06-20End: 2020-11-30Updated: 2021-03-18

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

TerminatedNCT04822701

Boehringer IngelheimCOVID-19

Start: 2021-04-21End: 2021-10-04Updated: 2022-07-28

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

WithdrawnNCT04894474

Boehringer IngelheimCOVID-19

Start: 2021-06-17End: 2022-07-24Updated: 2021-11-08